← FDA DRUG APPROVALS

FDA NDA · NDA021110

SIROLIMUS

Sponsor: PF PRISM CV

APPLICATION
NDA021110
TYPE
NDA
ORIGINAL APPROVAL
2000-08-25
LATEST ACTION
2022-08-22
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription, Discontinued

Products

RAPAMUNE · ReferencePrescription
SIROLIMUS 0.5MG · TABLET · ORAL
RAPAMUNE · ReferencePrescription
SIROLIMUS 2MG · TABLET · ORAL
RAPAMUNE · ReferenceDiscontinued
SIROLIMUS 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL
RAPAMUNE · ReferencePrescription
SIROLIMUS 1MG · TABLET · ORAL

Approval history

2022-08-22Labeling · Supplement 87 · standardLetterAP
2022-08-22Labeling · Supplement 88 · standardLetterAP
2021-08-09Labeling · Supplement 86 · standardLetterAP
2020-01-02Labeling · Supplement 85 · standardLetterAP
2019-07-15Labeling · Supplement 83 · standardLetterAP
2019-04-05Labeling · Supplement 84 · standardLabelAP
2018-05-23Labeling · Supplement 80 · standardLetterAP
2018-01-12Labeling · Supplement 81 · standardLabelAP
2017-04-11Labeling · Supplement 76 · standardLabelAP
2015-11-05Labeling · Supplement 75 · standardLetterAP
2015-05-28Efficacy · Supplement 73 · priorityLabelAP
2015-03-30Manufacturing (CMC) · Supplement 72 · standardAP
2015-03-06Labeling · Supplement 74 · standardLabelAP
2014-07-03Manufacturing (CMC) · Supplement 71 · standardAP
2014-01-29Manufacturing (CMC) · Supplement 70 · standardAP
2013-11-06Manufacturing (CMC) · Supplement 69 · standardAP
2013-05-30Labeling · Supplement 68 · standardLetterAP
2013-03-07Labeling · Supplement 67 · standardLetterAP
2012-12-10Labeling · Supplement 65 · standardLetterAP
2011-07-11Labeling · Supplement 59 · unknownLetterAP
2011-06-06REMS · Supplement 60LetterAP
2010-11-23Labeling · Supplement 57 · 901 requiredLetterAP
2010-11-23Labeling · Supplement 55 · unknownLetterAP
2010-11-08Labeling · Supplement 58 · unknownLetterAP
2010-07-02Labeling · Supplement 56 · unknownLetterAP
2010-04-22Labeling · Supplement 53 · unknownLabelAP
2010-04-22Labeling · Supplement 54 · unknownLetterAP
2010-01-25Manufacturing (CMC) · Supplement 52 · standardLabelAP
2009-10-08Labeling · Supplement 51 · 901 requiredLetterAP
2009-09-24Labeling · Supplement 50 · standardLabelAP
2009-01-29Labeling · Supplement 49 · standardLabelAP
2008-03-05Labeling · Supplement 47 · standardLetterAP
2008-03-05Labeling · Supplement 48 · standardLetterAP
2008-01-14Efficacy · Supplement 43 · standardLetterAP
2007-10-17Labeling · Supplement 45 · standardLetterAP
2007-05-02Labeling · Supplement 39 · standardLetterAP
2007-01-30Efficacy · Supplement 37 · unknownLetterAP
2007-01-12Labeling · Supplement 38 · standardLabelAP
2007-01-09Labeling · Supplement 35 · standardLetterAP
2006-10-19Labeling · Supplement 36 · standardLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →